Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Amicus Therapeutics benefits from strong revenue and limited competition. Learn why FOLD stock is a BUY, with a favorable ...

BRIDGEWATER, NJ, USA I March 14, 2025 I Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug ...

Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing.

While early-stage, the Adagene deal is another example of Sanofi's determination to bolster its R&D pipeline via a string of deals, including a $5.2 billion, strategic-level alliance with UK ...

Key players in the sinusitis drug pipeline market include Bayer, Sanofi, and Pfizer, among others. These companies are at the forefront of developing cutting-edge therapies to improve patient outcomes ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...